SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Monsanto Co.
MTC 2.8200.0%Dec 2 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: jttmab who wrote (909)1/17/1999 12:54:00 AM
From: Anthony Wong  Read Replies (1) of 2539
 
James, I've copied your post re. the articles to the PFE thread and this is a response:

To: Anthony Wong (6720 )
From: John R. Sashko
Saturday, Jan 16 1999 4:54PM ET
Reply # 6723 of 6726

The articles are about different arms in the pathways of prostaglandin production.

The one states that celebrex doesn't affect thromboxane A2 like motrin does.
Thomboxane leads to platelet aggregation and vasoconstriction. Inhibiting a stimulator
too much leads to those nasty GI bleeds. But on the other hand, this is what you want to inhibit when you take 2 baby aspirins per day to prevent the annoying MI's & CVA's.

The other is about Cox-2 inhibitors affect on prostacyclin. Prostacyclin is an inhibitor of platelet aggregation and causes vasodilation. The concern is that inhibiting the inhibitor may lead to thrombosis.

Time will tell if this is a real concern. A big part of the market for Celebrex will be in the geriatric population, where NSAID induced ulcers are frequently silent until they present with the GI bleed. I don't believe that physicians will wait for studies to suggest that their elderly patients should take 2 baby aspirin daily with the Celebrex since they should already be advising it for the males over age 50.

Next







Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News